Recognising the rapid progress and growing importance of the therapeutic application of nuclear medicine, the NMEU Therapy working group was created to give voice to this evolving, cutting-edge sector and to highlight the leading role of all players in the industrial sector in the value chain of radiopharmaceutical production for the benefit of patients.

The working group brings insights from the therapeutic side of nuclear medicine into the activities of NMEU, alongside the role of diagnostics.
The working group welcomes and includes all the diversity of technical, scientific, regulatory and medical expertise necessary for theranostic applications and their dissemination.

The Therapy working group meets with the other working groups to cross-discuss issues of shared relevance, related to, in particular, production engineering and facilities, radiation protection, dosimetry, medicinal products, procurement, regulation, management of hospital radioactive waste, health technology assessment and reimbursement policies.

The Working group develops opinions and positions on therapeutic perspective. It ensures that these positions are well recognised and featured in key policy files at the EU and national levels. Among its other activities, the group identifies and interacts with relevant stakeholders and EU institutions, collaborates and participates in official publications, public responses and further NMEU engagement activities.

The scope of the working group’s activities is two-fold. Firstly, the group strives to establish the therapeutic applications of nuclear medicine as an innovative treatment paradigm – not only in the field of oncology but also in other disease areas. Secondly, the group intends to reduce the gap between industry and academic research and encourage greater collaboration between the two parts to be “stronger together for patients” (e.g.: through organisation of seminars, hot topics sessions, development of short papers for dissemination, etc.).

Ultimately, the group seeks to promote the adoption of therapeutic applications of nuclear medicine through suitable legislation and equipped healthcare systems. In this way, we will achieve a better regulatory and policy environment for the uptake of therapeutic nuclear medicine at European and national levels.